207 related articles for article (PubMed ID: 26957556)
1. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
2. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
3. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
5. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia].
Yao L; Xu W; Fan L; Miao KR; Wu YJ; Qiao C; Zhu DX; Zhu HY; Liu P; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):36-9. PubMed ID: 20137114
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T
Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733
[TBL] [Abstract][Full Text] [Related]
8. [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
Yao L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):821-4. PubMed ID: 20561458
[TBL] [Abstract][Full Text] [Related]
9. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
13. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
14. Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Perez-Chacon G; Martinez-Laperche C; Rebolleda N; Somovilla-Crespo B; Muñoz-Calleja C; Buño I; Zapata JM
Clin Cancer Res; 2016 Jan; 22(1):134-45. PubMed ID: 26324744
[TBL] [Abstract][Full Text] [Related]
15. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
[TBL] [Abstract][Full Text] [Related]
16. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
17. MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells.
Ashofteh N; Amini R; Molaee N; Karami H; Baazm M
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2191-2198. PubMed ID: 34319043
[TBL] [Abstract][Full Text] [Related]
18. The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia.
Podhorecka M; Klimek P; Chocholska S; Szymczyk A; Macheta A; Kowal M; Dmoszynska A; Hus M
Eur J Clin Pharmacol; 2015 Sep; 71(9):1121-7. PubMed ID: 26141594
[TBL] [Abstract][Full Text] [Related]
19. The treatment of relapsed refractory chronic lymphocytic leukemia.
Brown JR
Hematology Am Soc Hematol Educ Program; 2011; 2011():110-8. PubMed ID: 22160021
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
Johnson AJ; Lucas DM; Muthusamy N; Smith LL; Edwards RB; De Lay MD; Croce CM; Grever MR; Byrd JC
Blood; 2006 Aug; 108(4):1334-8. PubMed ID: 16670263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
